Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by jopatcloon Nov 13, 2024 2:04pm
31 Views
Post# 36310766

RE:RE:RE:👀Fud Before no sales &now there been essentially no sales😉

RE:RE:RE:👀Fud Before no sales &now there been essentially no sales😉GranhamB the vulture see  Interesting on Linkedin Hannah Crane Clinical Applications Specialist & Cardiac Sonographer Ventripoint Diagnostics Ltd. Likes this (Us2.ai has a feature that leverages the speed of our AI) post Seth Koeppel .Business Development 22h • Was chatting with some #echo enthusiasts recently and realized I should share a very useful and powerful application of #AI in #echocardiography: longitudinal comparison of multiple echos of a single patient can offer significant clinical benefit but is often too time consuming to be practical. Us2.ai has a feature that leverages the speed of our AI, analyzing multiple patient echos in ~2-mins, then graphing each parameter longitudinally and presenting the annotations side by side (including GLS), removing operator variability and bias in the process (our AI is 100% reproducible). Imagine analyzing 3-4 echos of a patient in just a few minutes with zero human intervention and zero clicks required :-)
& see
 & Us2.ai On Ascend website https://ascendcv.com/ Ascend The BEST automation and analysis of the PLANET GEN3EHO CLICK TO LEARN MORE and CLICK ON Integrations Very interesting see on Us2.ai Seamless, flexible integration with heterogeneous AI, imaging and enterprise IT environments enables a best-of breed approach. Examples include: Us2.ai - Benefit from the the industry’s most sophisticated integration of Us2.ai. Us2.ai FDA-approved measurements feed ASE-validated suggested interpretations that can automatically complete the echo report Save time with single-click navigation to the automated measurement source frame 1-click sync to automated measurement frame Distinct review processes for FDA-cleared versus investigational measurements, enhancing compliance and clarity Automatic grouping of Us2.ai measurements accelerates the measurement review process Visual notification of user edits performed on Us2.ai measurements promotes transparency and traceability Engineered for seamless integration: Gen3Echo was designed with commitment to openness, seamlessly integrating with AI, ML, and advanced visualization software to foster innovation and collaboration. Ventripoint - The integration of Gen3Echo with Ventripoint’s innovative application of AI to echocardiography provides tremendous value to pediatric and adult echocardiographers in caring for their most complex patients. Ventripoint’s VMS product is powered by its proprietary KBR technology and provides accurate volumetric cardiac measurements with sMRI levels of accuracy. It can be used with all ultrasound systems supported by regulatory market approvals and is seamlessly integrated into the reading workflow enhancing diagnostic precision and treatment planning, ultimately improving the quality of pediatric care.

<< Previous
Bullboard Posts
Next >>